Ergoteles’s Trueblue TBI Stock Holding History

Ergoteles’s Portfolio TBI Stock Details TBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,800	Closed	-$225K	–	1867
2022 Q3	$225K	Sell	11,800 -3,100	-21%	-$62.7K	0.01%	1115
2022 Q2	$267K	Buy	14,900 +2,593	+21%	+$60.9K	0.01%	1167
2022 Q1	$356K	Buy	+12,307	New	+$338K	0.01%	787

Other funds holding TBI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ergoteles's TBI Position: Q4 2022 in Review

Ergoteles sold out of Trueblue (TBI) in Q4 2022, closing a stake of 11,800 shares — an estimated $225K sold.

Ergoteles first reported a position in TBI in Q1 2022 and held it in 3 quarters. The position peaked at $356K in Q1 2022. 164 funds tracked by Wall St. Rank hold TBI as of Q4 2022.

Ergoteles reported no remaining Trueblue position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 11,800 Trueblue shares in Q4 2022, an estimated $225K.
Ergoteles first reported a position in Trueblue in Q1 2022 and held it in 3 quarters.
Ergoteles's Trueblue position peaked at $356K in Q1 2022.
164 funds tracked by Wall St. Rank held Trueblue as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.